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AKTIVITI ANTIHIPERLIPIDEMIK POLYGONUM MINUS  
DAN ELUSIDASI MEKANISME TINDAKANNYA 
 
ABSTRAK 
Polygonum minus merupakan tumbuhan herba yang ditanam di  negara Asia 
Tenggara.  Ia merupakan salah satu daripada herba yang digunakan secara meluas di 
Malaysia sebagai pengawet makanan,  ulam dan ubatan herba bagi mengubati pelbagai 
penyakit. Kajian ini bertujuan untuk menilai kesan hiperlipidemik  ekstrak  daun P. 
minus  termasuklah mekanisma, aktiviti antioksida serta ketoksikan tumbuhan ini. 
Kesan ekstrak akueus dan metanol daun P. minus (1000 mg/kg) diuji pada tikus 
hiperlipidemik yang diaruh menggunakan polaxamer-407 bagi kajian 
antihiperlipidemik. Atorvastatin (60 mg/kg) digunakan sebagai rujukan piawai. Kajian 
ini menunjukkan kedua dua ekstrak menurunkan kolesterol total, trigliserida, LDL, 
indeks atherogenik  dan meningkatkan paras HDL apabila dibandingkan dengan 
kawalan hyperlipidemia bagi ekstrak metanol dibandingkan dengan ekstrak akueus. 
Berdasarkan keputusan yang diperolehi, ekstrak metanol daun P. minus dipilih bagi 
kesan anti-hiperlipidemik kronik hiperlipidemia. Model tikus yang diaruh 
hiperlipedemia dengan diet tinggi lemak digunakan bagi menilai kesan anti-
hiperlipidemik ekstrak metanol pada dos 250, 500 dan 1000 mg/kg. Kajian ini menilai 
kesan ekstrak metanol (1000 mg/kg) pada tikus normal dan tikus dengan diet tinggi 
lemak. Tiada sebarang perubahan signifikan pada lipid dan parameter lain pada tikus 
normal dan tikus yang diberi diet tinggi lemak manakala perubahan signifikan 
diperolehi bagi tikus diet tinggi lemak yang diberi dos berbeza terutamanya 500 dan 
1000 mg/kg ekstrak apabila dibandingkan dengan kawalan hiperlipidemik. Efek ekstrak 
dapat dibandingkan dengan dadah kawalan, atorvastatin (20 mg/kg). Keputusan yang 
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diperolehi ini menunjukkan kesan ekstrak P. minus adalah bersifat anti-hiperlipidemik 
dan bukannya hipolipidemik kerana paras parameter lipid pada tikus normal tidak 
berubah. Kandungan fenolik dan flavonoid didapati lebih tinggi pada ekstrak metanol 
dan memberi aktiviti antioksida yang lebih tinggi berbanding ekstrak akueus. Aktiviti 
anti-hiperlipidemik  ekstrak metanol diperolehi melalui pelbagai mekanisma  
termasuklah peningkatan aktiviti antioksida  in-vivo, perencatan enzim HMG-CoA 
reductase, penurunan paras kolesterol di dalam hati, sintesis trigliserida, peningkatan 
aktiviti penyingkiran kolesterol dan hempedu melalui tinja. Kajian ketoksikan 
dijalankan bagi menilai aspek keselamatan ekstrak. Analisa kandungan  logam berat 
menunjukkan ekstrak akueus dan metanol adalah bebas dari logam berat. Aktiviti 
sitotoksik pada sel normal (EA.hy926) dan kanser (HCT116, HT29 dan HeLa) 
menunjukkan kedua dua ekstrak adalah tidak sitotoksik.  Aktiviti ketoksikan akut dan 
sub-kronik menunjukkan ekstrak metanol  daun P. minus adalah selamat pada dos 
sehingga 2000 mg/kg kerana ekstrak tersebut tidak menunjukkan sebarang tanda tanda 
ketoksikan berdasarkan berat badan, berat organ, berat relatif organ, parameter 
biokimia dan hematologi serta histologi sel. Kuersetin dan miresetin dikenalpasti dalam 
ekstrak metanol dan kandungannya dinilai menggunakan HPLC. Kajian ini 
menunjukkan P. minus mempunyai kesan penurunan lipid dan boleh dibangunkan 
sebagai agen anti-hiperlipidemik. 
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ANTIHYPERLIPIDEMIC ACTIVITY  
OF POLYGONUM MINUS AND ELUCIDATION OF ITS  
MECHANISM OF ACTION 
 
ABSTRACT 
Polygonum minus is an herbaceous plant grown naturally and cultivated 
throughout Southeast Asian countries. It is one of the widely used herbs in Malaysia as 
food additive, salad leaves (Ulam) and as traditional medicine to treat different 
ailments. Present study aims to evaluate the antihyperlipidemic effect including 
possible mechanism, antioxidant capacity and toxicities of extract of P. minus leaves. 
In acute antihyperlipidemic study, the effect of aqueous and methanol extracts of P. 
minus leaves (1000 mg/kg) were tested on poloxamer-407 induced acute 
hyperlipidemia in rats. Atorvastatin (60 mg/kg) was used as standard drug. The study 
showed that both extracts reduced the total cholesterol (TC), triglycerides (TG), LDL, 
VLDL, atherogenic index, and increased HDL levels when compared with 
hyperlipidemic control and the effect was higher in methanol extract when compared to 
aqueous extract. Based on this result, methanol extract of P. minus leaves was selected 
for determination of antihyperlipidemic effect in chronic hyperlipidemia. High fat diet-
induced hyperlipidemia rat model was employed to evaluate the antihyperlipidemic 
effect of P. minus leaves methanol extract at doses of 250, 500 and 1000 mg/kg. There 
were no significant changes in the lipid and other parameters observed in the normal 
rats treated with high dose of extract whereas significant alterations were evident in 
high fat diet fed rats treated with different doses especially at 500 and 1000 mg/kg 
extract when compared with hyperlipidemic control. The effect of the extract was 
comparable with standard drug atorvastatin (20 mg/kg). This finding suggests that the 
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effect of P. minus extract is antihyperlipidemic rather than hypolipidemic as the levels 
of lipid parameters in the normal rats was not affected. Phenolic and flavonoids content 
were found to be high in methanol extract leading to better antioxidant activity than 
aqueous extract. Antihyperlipidemic effect of methanol extract was achieved via 
multiple mechanisms including elevation of in vivo antioxidant activity, in part by 
inhibition of HMG-CoA reductase enzyme, reduction in hepatic cholesterol and 
triglyceride synthesis and increased excretion of cholesterol and bile acids through 
feces.  Toxicity studies were conducted to assess the safety of the extract. The heavy 
metal content analysis suggested that the aqueous and methanol extracts are devoid of 
toxic heavy metals. The cytotoxicity studies on normal (EA.hy926) and cancer 
(HCT116, HT29 and HeLa) cells showed that both the extracts were not cytotoxic. 
Acute and sub-chronic toxicity studies found that the methanol extract of P. minus 
leaves was safe to administer orally up to 2000 mg/kg of body weight as the extract did 
not cause any signs of toxicity in body weight, relative organ weight, biochemical and 
hematological parameters and cell histology. Biomarkers such as quecitrin and 
myricetin were identified in methanol extract and the amounts were quantified using 
HPLC (5.5 and 0.6 µg/mg respectively). In conclusion, this study suggests that P. 
minus possess lipid-lowering effect and could be potentially developed as an 
antihyperlipidemic agent.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Background 
Cardiovascular disease (CVD) is one of the four major non-communicable 
diseases which cause significant mortality in the world. These diseases are 
manifested as coronary heart disease (CHD), cardiomyopathy, strokes, rheumatic 
heart disease (RHD) and other heart diseases (Fakhrzadeh and Tabatabaei-Malazy, 
2012; Celermajer et al., 2012). About one third of the global death was caused by 
CVD in 2020 and is expected to be one of the major health risks by 2020. The rate of 
mortality caused by CVD is predicted to rise dramatically in the coming decades. 
Dyslipidemia is one of the main metabolic comorbidities associated with excessive 
body fat that contribute as major factor to the development of CVD. It is projected 
the rate of mortality and morbidity due to CVD could be raised as the prevalence of 
various CVD risk factors rise as a result of adverse changes in way of life due to 
urbanization and industrialization. Obesity caused by lipid metabolic syndromes is 
one of the serious health issue faced by both industrialized and developing world. 
Over 115 million people in the world are suffering with obesity and its related 
problems (Adeboye et al., 2012). CVD is one of the prime causes of mortality in 
Malaysia in 1970 and the rate of mortality is still increasing with CHD. Many other 
studies also have found that the prevalence rate of CVD in Malaysia is alarming 
(Jeyamalar, 1991; Yunus et al., 2004). The treatment of CVD is based on life style 
modifications and drug therapy. Hyperlipidemia is the main risk factor to develop 
CVD. Mainly five classes of drugs are utilized to treat hyperlipidemia condition; 
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statins, fibtrates, derivatives of nicotinic acid, bile acid sequesterants and inhibitors 
of cholesterol absorption (Rohilla et al., 2012). Even though they are very effective 
and beneficial in treating hyperlipidemia, their adverse effects are limiting factors in 
the treatment of hyperlipidemia. The development of effective but less toxic 
antihyperlipidemic agents are the present focus. The current interest has extended to 
develop novel lipid lowering molecules from natural sources with efficacy and 
minimal toxicity (Saghir et al., 2014; Ibrahim et al., 2013).  
Atherosclerosis is one of the common pathophysiological features to cause 
cardiovascular diseases. Atherosclerosis develops by the combination of several 
environmental and genetic factors but the pathogenesis of this condition is 
principally due to lipoproteins. Many studies have established the solid relationship 
between increased LDL level and occurrence of atherosclerosis. Reduction in the 
LDL level remains as the main stay in the primary target of the treatment (Kastelein 
et al., 2008; Adams, 2005). Dyslipidemia is one of the major risk factor of CVD and 
it is manifested by increased lipoprotein concentration in plasma. It is a highly 
heterogeneous class of metabolic disorder, characterized by altered serum plasma 
protein levels. Generally dyslipidemia includes hyperlipidemia 
(hypercholesterolemia) and low levels of HDL (Bersot, 2011; Fakhrzadeh and 
Tabatabaei-Malazy, 2012).  
In epidemiological studies, LDL has been identified as atherogenic. The 
relationship between new onset of CHD and LDL is also an established fact. The 
recurrence of cardiac events in CHD patients are also related with LDL level (Wilson 
et al., 1998). The decreased level of HDL is also an important factor which increases 
the CHD risks. It is reported that 1% decrease in HDL may increase 2-3% risk of the 
CHD. An increased association between TG level and CHD risk was confirmed by 
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many investigations. The raised TG level significantly correlated with CHD risk and 
the atherogenic potential of some TGs have confirmed. Non-HDL cholesterol level is 
a better indicator of CHD risk than HDL level. A condition of low HDL, high TG 
and small dense LDL (highly atherogenic) particles but normal LDL level, 
atherogenic dyslipidemia, is also a risk factor for CHD (Desforges et al., 1989; 
Sarwar et al., 2007; Rubins et al., 1999; Lu et al., 2003).  
1.2 Therapeutic challenges 
A substantial proportion of deaths in developing countries are due to 
cardiovascular diseases. It is projected that 80-90% of the cardiovascular patients 
will be in under developed or developing countries by 2025. The disability adjusted 
life years (DALY) of premature morbidity and mortality associated with CVD is 
expected to double from 85 million in 1990 to 140-160 million in 2020 (Yusuf et al., 
2002). The Malaysian scenario of coronary artery disease is a good reflection of the 
disease in most developing countries. According to the report of ‗The National 
Health and Morbidity Survey, (NHMS), the prevalence rate of atherosclerosis is 
dangerously increasing when compared with the previous data. About 47.7% (9.6 
million) Malaysian adults of 18 years and above have hypercholesterolemia, in that 
9.7% have already diagnosed with hypercholesterolemia and the remaining 38.6% 
was undiagnosed previously (Institute of Public Health, 2015). Hyperlipidemia is 
associated with many other metabolic disorders such as atherosclerosis, obesity, 
diabetes mellitus, renal disorders, liver disorders, thyroid disorders, Cushing‘s 
syndrome, hepatic lipase deficiency and glycogen storage diseases, so the treatment 
of hyperlipidemia is also related with the coexisting disorders (Ibrahim et al., 2013). 
Diverse classes of drugs are available to manage hyperlipidemia. Even though they 
are effective, their adverse effects are considered to be serious. The side effects 
4 
 
include rhabdomyolysis, elevation of hepatic enzymes, myopathy, and increased risk 
of gall stones (Expert Panel on Detection, 2001). The escalating costs of these 
synthetic drugs are also a major clinical challenge. There is no single drug or class of 
drug is effective against all sorts of hyperlipidemia (Alsheikh-Ali et al., 2004). The 
demand for high efficacy, minimal side effect, low cost and multiple targeting in 
preventing and curing antihyperlipidemic agents are need of the day.  
1.3 Problem statement  
 Prevention of hyperlipidemia using drugs with minimum adverse effects and 
cost effectiveness remained unresolved therapeutic challenges in the management of 
hyperlipidemia associated metabolic disorders.  People residing in areas with rich 
biodiversity usually depend upon medicinal plants to cater their daily health needs. 
Traditional medicines have significantly contributed to the development of 
successful drugs for various health conditions. Polygonum minus is such a plant and 
commonly available throughout Malaysia. Traditional uses and various 
pharmacological activities including excellent antioxidant capacity for this plant 
were reported (Qader et al., 2012a; Narasimhulu and Mohamed, 2014). This plant is 
believed to have lipid lowering effect and consumed as salad leaves along with other 
plant leaves (Jaganath and Ng, 2000). There were no previous studies available on 
the lipids lowering effect of P. minus in any animal models other than an in vitro 
study evaluated its inhibitory effect on LDL oxidation (Saputri and Jantan, 2011). 
The notable scarcity of scientific studies to prove or challenge the traditional claim 
on lipids lowering effect created an interest to evaluate the potential 
antihyperlipidemic effect, investigate the probable mechanism of lipid lowering 
property and assesses the toxicity due to regular consumption of P. minus.  
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1.4 Objectives 
The objectives of the present study are: 
i. To evaluate the antihyperlipidemic effect of aqueous and methanol extracts of 
leaves of P. minus on chemical-induced acute hyperlipidemic rat model 
ii. To evaluate the antihyperlipidemic effect of the most active extract of leaves 
of P. minus on diet-induced chronic hyperlipidemic rat model 
iii. To evaluate the antioxidant capacity of aqueous and methanol extracts of 
leaves of P. minus  
iv. To evaluate the mechanism of antihyperlipidemic effect of the most active 
extract of leaves of P. minus on 
a. Inhibition of lipid synthesizing enzymes 
b. Lipids and bile acid excretion 
c. In vivo antioxidant capacity and lipid peroxidation 
v. To evaluate the toxicity of the most active extract of leaves of P. minus 
vi. To standardize the most active extract of leaves of P. minus using selected 
marker compound 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Lipids  
The word lipid was coined by G. Bertrand in 1923 from Greek lipos (grease 
or fat) and French chemical suffix –ide. The exact definition for lipids does not exist. 
Lipids comprise wide range of natural products including terpenes, fatty acids and 
bile acids. They are chemically heterogeneous substances, readily soluble in non-
polar solvents but insoluble in water. Lipids are classified according to their physical 
properties, polarity, human requirement and structure. Physically lipids are classified 
into liquids and solids. They are classified as essential and non-essential fatty acids 
according to human requirement and structurally they are divided into simple and 
complex lipids (Akoh and Min, 2008).  
Simple lipids are esters of unsaturated fats with various alcohols, mainly fats 
and waxes. Compound lipids are simple lipids containing other groups along with an 
alcohol and a fatty acid. They are mainly phospholipids, glycolipids and other 
complex lipids. Lipids have additional functions in the body such as fat-soluble 
vitamins, coenzymes and steroid hormones. The deficiencies or imbalance of lipid 
metabolism leads to major clinical problems.  
 
2.1.1 Fatty acids 
Fatty acids (FAs) are carboxylic acids containing long chain hydrocarbon 
side groups. Fatty acids occur in the body as esters, but it is found to be free fatty 
acids in the plasma. Fatty acids are stored as triacylglycerols. They functioned as the 
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fuels for body by providing energy. Most fatty acids possess even number of carbon 
atoms since they are synthesized by C2 units‘ concatenation. Alterations in the fatty 
acid metabolism are associated with obesity and diabetes.  The role fatty acids in 
biological systems involve different mechanism of action. The roles and mechanisms 
of are outlined in Figure 2.1 
 
Figure 2.1: Scheme of mechanisms of action for fatty acids- adapted from Rustan 
and Drevon, (2005).  
 
2.1.2. Phospholipids 
Phospholipids made up of two fatty acids, a glycerol unit, a phosphate group 
and a water soluble molecule. They frequently have nitrogen-containing bases and 
substituent. They are regarded as the derivatives of phosphatidic acid. The phosphate 
group and water soluble head region of the molecule is hydrophillic while the fatty 
acid tail is hydrophobic. When placed in water, phospholipids will situate themselves 
into a bilayer in which the non-polar region faces the inner area. Phospholipids are 
the predominant cell membrane lipids. Membrane phospholipids functions as a 
storage depot for intracellular messengers where as non-membrane phospholipids are 
functions as lung surfactant and essential components of bile.  
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2.1.3. Triglycerides 
Neutral fats are also called as triglyceride (TG) or triacylglycerol. It is 
classified under simple lipids. These comprise esters of, glycerol, trihydric alcohol 
with fatty acids.  The old names like monoglyceride, diglyceride and triglyceride 
were corrected to monoacyl glycerol, diacyl glycerol and triacyl glycerol by 
International Union of Biochemistry. But the old popular names are still in use. 
Triacylglycerols are hydrophobic and insoluble in water. They include oils and fats. 
Triacylglycerols are stored in the form of lipids in adipose tissues. Triglycerides are 
hydrolysed by lipases to di and monoacylglycerol (Vasudevan and Sreekumari, 
2006).  
Elevated levels of triglycerides are considered as a cardiovascular risk factor. 
The mild to moderately elevated concentration (2–10 mmol/L) of triglyceride 
lipoproteins can be a reason for atherosclerosis. It is reported that the raised level of 
fasting and non-fasting triglycerides (hypertriglyceridemia) were directly associated 
with the coronary heart diseases like myocardial infarction, ischemic heart disease, 
ischemic stroke and mortality caused by all of these diseases (Nordestgaard and 
Varbo, 2014). The suggested role of increased triglyceride level in the development 
of atherosclerosis is depicted in Figure 2.2. 
Triglyceridemia levels are classified as normal (less than 150 mg/dL; less 
than 1.70 mmol/L), borderline high (150 to 199 mg/dL; 1.71-2.25 mmol/L), high 
(200 to 499 mg/dL; 2.26-5.65 mmol/L), very high (greater than 500 mg/dL; greater 
than 5.66 mmol/L). The coagulability and viscosity of the blood is increased by 
hypertriglyceridemia and leads to atherothrombosis. Triglycerides have 
atherogenicity due to the rich presence of a polipoprotein C-III. These Apo C-III 
causes delay the breakdown of VLDL and block its plasma clearance. 
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Hypertriglyceridemia is usually connected with low HDL levels (Ducharme and 
Radhamma, 2008; Raza et al., 2004; de Graaf et al., 1991).  
 
 
 
Figure 2.2 The suggested role of increased TG level in the 
development of atherosclerosis- adapted from 
Nordestgaard and Varbo, (2014).  
  
FFA=free fatty acids, LPL=lipoprotein lipase. Triglycerides and 
remnant cholesterol could act through triglyceride hydrolysis and 
cholesterol accumulation in arterial wall foam cells leading to 
development of atherosclerosis. 
 
 
 
 
 
11 
 
2.1.4 Cholesterol and cholesterol esters 
The word cholesterol is originated from Greek words, chole-bile; steros-solid; 
ol-alcohol. Cholesterol is widely distributed and performs many essential functions 
in the body. It is the primary steroid from which other steroids are formed. The 
functions of the cholesterol are many and they include insulation of nerve fiber, 
component of membranes which maintain the fluidity, bile acids and salts are derived 
from cholesterol, source of steroid hormones and vitamin D etc. The imbalance 
between influx and efflux of cholesterol leads to its deposition in the tissue. The 
deposition on the lining of blood vessel leads to potentially life-threatening 
atherosclerosis (Harvey and Ferrier, 2011).  
 
 
[1] Cholesterol 
Cholesterol esters have long-chain fatty acids connected to the hydroxyl 
group. They are less polar when compared with free cholesterol. They are the 
transportation forms of cholesterol. Plasma cholesterols usually have high content of 
proteins due to the difference in synthesis. During membrane and lipoprotein 
formation, the cholesterol esters hydrolyzed to liberate cholesterol (Sebedio and 
Christie, 1998).  
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[2] Cholesterol ester 
Increased total cholesterol level in plasma has a direct correlation with 
increased risk of CHD. The maintenance of cholesterol level in the desirable level is 
important. The desirable total cholesterol level is less than 5 mmol/L. A total 
cholesterol level of 5 to 6 mmol/L is borderline high, whereas a value of 6 mmol/L or 
more is high. The therapeutic decisions are mainly made based on the LDL and HDL 
level rather than TC level (Ducharme and Radhamma, 2008).  
 
2.2 Lipoproteins 
Cholesterol is mainly synthesized in the liver and it must be transported to the 
cells where it is needed. Cholesterol is a lipid and insoluble in blood plasma. 
Cholesterol requires a transport carrier which can shield the aqueous nature of blood 
plasma. Lipoproteins, complex of various proteins and lipids achieve the vascular 
cholesterol transport. They are different in size, shape, composition and function. 
The lipoproteins are made up of a core of water insoluble lipids surrounded by 
phosphatidylglycerols and proteins. The lipoproteins are classified according to their 
density, the relative amount of lipids to protein in the complex. The density of the 
lipoproteins increases as the protein content increases. Chylomicrons (lowest 
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density), VLDLs (Very low density lipoproteins), IDLs (Intermediate density 
lipoproteins), LDLs (Low density lipoproteins) and HDLs (High density 
lipoproteins) are the major lipoproteins help in the transport of cholesterol (Daniels 
et al., 2009).  
Apoproteins (Figure 2.3) are the protein component present on the outer 
surface of lipoproteins. They function as receptors at cell surface and regulation of 
enzymes. Apoproteins usually dissociate from lipoproteins and bind with another 
except apoprotein B. Metabolism of apoproteins are important as any defect may 
disturb the lipid handling (Brunton et al., 2011).   
 
 
Figure 2.3: Typical structure of a lipoprotein- adapted from Harvey and Ferrier, 
(2011).  
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Physical properties and roles of major classes of lipoproteins (Voet and Voet, 2011) are summarized in Table 2.1 
Table 2.1: Physical properties and roles of major classes of lipoproteins 
 Chylomicrons VLDL IDL LDL HDL 
Source 
Synthesized from the 
fatty acids of dietary 
TGs and cholesterol 
by intestinal 
epithelial cells 
Produced in the liver 
when TG production is 
stimulated by an 
increased flux or de novo 
synthesis of fatty acids 
Formed 
during the 
transition of 
VLDL to 
LDL 
Arise from 
the 
catabolism 
of IDL 
Multiple mechanisms 
by which HDL 
particles are formed in 
blood, liver and 
intestine. 
Density (g/cm
3
) <0.95 <1.006 1.006-1.019 1.019-1.063 1.063-1.210 
Particle diameter (Å) 750-12000 300-800 250-350 180-250 50-120 
Particle mass (kD) 400000 10000-80000 5000-10000 2300 175-360 
Surface components      
 %Protein 1.5-2.5 5-10 15-20 20-25 40-55 
 %Phospholipids 7-9 15-20 22 15-20 20-25 
 %Free cholesterol 1-3 5-10 8 7-10 3-4 
Core lipids      
 Triacylglycerols 84-89 50-65 22 7-10 3-5 
 Cholesterol esters 3-5 10-15 30 35-40 12 
Major 
apolipoproteins 
A-I, A-II, B-48, C-I, 
C-II, C-III, E 
B-100, C-I, C-II, C-III, E 
B-100, C-I, 
C-II, C-III, E 
B-100 
A-I, A-II, C-I, C-II, C-
III, D, E 
Role 
Transport exogenous 
TGs and TC from the 
intestine to tissues 
A group of related particles.  
They transport endogenous TGs and TC from liver to 
tissues. 
Transport endogenous 
TC from tissues to liver 
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2.3 Bile acids 
Bile acids (BAs) contain 24 carbon atoms. They are synthesized in the liver 
from cholesterol. All of them have α hydroxyl and β methyl group so that they 
exhibit both polar and non-polar nature and act as emulsifying agents. In the intestine 
it helps the lipid degradation by pancreatic enzymes. Different types of bile acids 
were identified (Chenodeoxycholic acid, ursodeoxycholic acid, deoxycholic acid, 
hyocholic acid,β-muricholic acid and cholic acid) from bile of different mammalian 
groups. Cholic acid (CA) and chenodeoxycholic acid (CDCA) are common to many 
species including human but some bile acid like ursodeoxycholic acid is specific to 
bear. The hamster bile acids are almost comparable with human (Agellon, 2002). 
Cholic acid and chenodeoxycholic acid are free bile acids while many others are 
conjugated bile acids. Bile acid acts as signaling molecules. They enter in the 
nucleolus and interact with nuclear receptors to stimulate or inhibit its own and its 
precursor, cholesterol production. Bile acids play important role in the cholesterol 
homeostasis (Stamp and Jenkins, 2008).  
Apart from the emulsification and absorption of lipids, BAs have many roles. 
Bile acid-dependent bile flow, stimulation of bilary lipid secretion, emulsion 
formation of lipid soluble vitamins in the gut and their absorption, facilitate intestinal 
calcium absorption, modulation of pancreatic enzymes and cholecystokinin and 
prevention of small intestinal bacterial over growth are the important physiological 
roles of BAs (Monte et al., 2009).  
Liver is the major site of BA synthesis. About 500 mg of cholesterol in an 
adult human is converted to bile acids every day. There are two main synthetic 
pathways, classical and alternative pathways accounted for the formation of BAs. 
The other minor pathways are relevant in some species. The classical pathway is also 
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called as neutral pathway due to the formation of neutral sterol intermediate 
metabolites. This route synthesizes two types of bile acids in human, CA and CDCA. 
The series of reactions in this route are catalyzed by enzymes in mitochondria, 
cytosol, peroxisomes and microsomes (Russell, 2003).   
In the neutral pathway, about 12 enzymatic reactions are carried out for the 
conversion of water insoluble cholesterol to water soluble BAs. The cholesterol is 
first converted to 7-alpha-hydroxy cholesterol, followed by cascades of enzymatic 
reactions. The cytochrome P-450 enzyme, cholesterol 7 alpha hydroxylase (CYP 
7A1), expressed in the liver is a rate-limiting enzyme of this conversion. The final 
step in BA synthesis is the amino acids glycine or taurine conjugation with terminal-
side chain carboxylic acid. This step is mediated by bile acid CoA: amino acid N-
acyltransferase (BAAT). The elaborated classical pathway is depicted in Figure 2.4.  
In the alternative pathway, the intermediates formed are acidic in nature so 
the pathway is regarded as acidic pathway. The first step is the oxidation of 
cholesterol to 27-hydroxycholesterol by sterol 27-hydroxylase (CYP27A1), then it is 
converts into 7α, 27-dihydroxycholesterol by microsomal oxysterol 7α-hydroxylase 
(CYP7B1). The oxidized sterols must be transported to the liver to be converted to 
bile acids because the enzyme for that is available only in the liver. CDCA is the 
main bile acid formed in this pathway. 
Alternative pathway may turn into the major bile acid biosynthetic pathway 
in patients with liver disorders (Agellon, 2002). The amount of bile acid in the body 
is closely regulated in liver and intestine to inhibit the accumulation thereby 
cytotoxicity (Hofmann, 1999).  
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Figure 2.4: Scheme of classical pathway of bile acid synthesis- adapted from Monte 
et al., (2009). 
 
 AKR1C4: 3α-hydroxysteroid dehydrogenase; AKR1D1: Δ4–3-oxosteroid-5β-
reductase; AMACR: Alpha methylacyl-CoA racemase; BAAT: Bile acid; CoA: 
Amino acid N-acyltransferase (
1
A minor cytosolic fraction does also exist); 
BACS: Bile acid CoA synthetase; BCOX: Branchedchain acyl CoA oxidase; 
BDP: D-bifunctional protein hydratase; CYP27A1: Sterol 27-hydroxylase; 
CYP7A1: Cholesterol 7α-hydroxylase; CYP8B1: Sterol 12α-hydroxylase; 
HSD3B7: 3β-hydroxy-Δ5-C27-steroid dehydrogenase/ isomerase; SCPx: Sterol 
carrier protein X; VLCS: Very long-chain acyl CoA synthetase; ER: 
Endoplasmic reticulum. 
 
2.4 Biosynthesis of cholesterol 
All carbon atoms of cholesterol are derived from acetyl CoA. Liver, adrenal 
cortex, testis, ovaries and intestine are the major sites of cholesterol synthesis. All 
tissues in human body synthesize cholesterol. The biosynthetic pathway was depicted 
by Sir John Cornforth and Vladimir Prelog and they were awarded with Nobel prizes 
in 1975. All nucleated cells can synthesize cholesterol and the enzymes involved in 
these reactions are located in endoplasmic reticulum as well as in cytoplasm.  
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The reaction starts with the condensation of two molecules of acetyl CoA 
mediated by cytoplasmic acetoacetyl CoA synthase to form acetoacetyl CoA. One 
more acetyl CoA molecule condenses to the acetoacetyl CoA and form HMG CoA 
by HMG CoA synthase. HMG CoA is present in the cytosol and mitochondria of the 
liver. The cytosolic HMG CoA pool is utilized to synthesis cholesterol. HMG CoA 
reductase reduces the HMG CoA to mevalonate, this step is unique to cholesterol 
synthesis where- as the two previous steps are common to ketogenic pathway. The 
reduction of HMG CoA to mevelonate is a rate limiting step. Mevelonate is 
phosphorylated and finally converted to 3-phospho 5-pyrophospho-mevelonate 
(mevelonate 5-PP). Decarboxylation of mevelonate 5-PP is to produce isopentyl 
pyrophosphate. All these steps are considered as the primary phase of cholesterol 
synthesis. The 5-carbon unit formed in the first phase is then condensed to give a 30 
carbon compound called squalene. These condensation reactions are catalyzed by 
many enzymes. Then squalene undergoes oxidation by epoxidase to form squalene 
epoxide and then it is converted to lanosterol by cyclase enzyme. The additional 
methyl groups are removed to form zymosterol. Double bond rearrangement leads to 
the formation of desmosterol. Finally, the double bond in the side chain is reduced by 
NADPH and the cholesterol is formed (Vasudevan and Sreekumari, 2006; Liscum, 
2002). The reaction summary of the cholesterol biosynthesis is given in Figure 2.5. 
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Figure 2.5: The cholesterol biosynthetic pathway, major intermediates and end-
products are indicated-adapted from Olivier and Krisans, (2000).  
 
       HMG; 3-hydroxy-3-methylglutaryl, DHC; dehydrocholesterol 
 
 
2.5 Digestion and absorption of lipids and cholesterol  
Natural fats, especially triglycerides are the major source of dietary lipids. 
Diet also contains minute quantities of cholesterol, phospholipids and cholesterol 
esters. The absorption of triglycerides is started in the stomach by lingual lipase, an 
enzyme secreted by Ebner's gland on the dorsal surface of the tongue. This 
metabolism is insignificant. The lingual lipase and gastric lipase along with the 
gastric motility and retropulsion the gastric content become a crude emulsion called 
as chime (Wilson and Rudel, 1994). Chyme is delivered to duodenum in small 
20 
 
quantities. Most of the fats are started to get digest in the duodenum. The pancreatic 
juice contains hydrolytic enzyme and bile contains bile salts. Together they 
contribute to the fat digestion. Pancreatic lipase is the most important enzyme along 
with phospholipase A2 and cholesterol esterase, involved in the duodenal fat 
digestion. Colipase is a pancreatic enzyme which was activated by trypsin and helps 
in the restoration of pancreatic lipase. The insoluble fat molecules are restricted to 
pass through the luminal membrane. They are well emulsified by the surfactant 
action of bile acids, lecithin and monoglycerides. Lipids and bile salts interact to 
form micelles. Formation of micelles facilitates the transport of fats across 
membrane. Then the lipids diffuse out of the micelles to the blood stream (Senior, 
1964). The presence of bile, fatty acids and pancreatic juice helps in the ready 
absorption of cholesterol from small intestine. The absorbed cholesterol is 
incorporated with chylomicrons and enters in to the lymphatics.  
 
2.6 Role of bile acids on cholesterol metabolism 
Regulation of cholesterol homeostasis and facilitation of small intestinal lipid 
digestion and uptake are the well-known functions of bile acids. Bile acids also 
regulate the synthesis and enterohepatic circulation of triglyceride, cholesterol and 
glucose. Cholesterol catabolism is mainly mediated by bile acids and they account 
about 50% of daily cholesterol turnover. The extent of bile acid excretion is believed 
to be the direct indication of cholesterol excretion but this hypothesis was discredited 
as 95% BA is reabsorbed in the ileum and through portal circulation transported back 
to liver. The remaining 5% BA is excreted and that deficiency is replenished by de 
novo synthesis in the liver. Excess cholesterol removal is not the main function of 
BA production in the body (Insull Jr, 2006; Lefebvre et al., 2009). Many 
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physiological functions of BA associated with cholesterol have been identified. 
Elimination of cholesterol is one of the most important among them. BAs convert 
cholesterol to bile acids, they increase the solubilization of cholesterol in bile and 
transport to ileum from liver cell, and then it is excreted through fecal route. Next 
main function is the transport of cholesterol from intestine as micelles. They diffused 
through the unstirred layer of mucosa, so the absorption of cholesterol is increased. 
The other function is the negative feedback regulation of cholesterol biosynthesis. 
The concentration of bile acid is a signal, when then concentration is low its hepatic 
synthesis will be increased. Cholesterol synthesis is also increased parallel to this 
(Vlahcevic et al., 1991).   
 
2.7 Excretion of cholesterol 
 The source of cholesterol in the body is from diet and synthesized de novo. 
About 300 mg of cholesterol is obtained from the diet normally whereas 700 mg is 
synthesized in the body itself. About 500 mg of cholesterol is excreted through bile 
but partly reabsorbed from the intestines. The unabsorbed portion interacts with 
intestinal flora and form cholestanol and coprostanol (fecal sterols). The remaining 
500 mg of cholesterol is converted to bile acids and then excreted as bile salts 
(Vasudevan and Sreekumari, 2006).  
 
2.8 Cholesterol metabolism 
The exogenous, endogenous pathways and reverse cholesterol transport are 
responsible for the generation and movement of cholesterol in human body.  
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2.8.1 Exogenous pathway 
The dietary fats are digested to form cholesterol and fatty acids along with 
bile. This mixture is absorbed to intestinal mucosa and they are re-esterified to form 
cholesterol esters and triglycerides. These combined with phospholipids and apoA 
and apoB and released in to lymph as chylomicrons. When the chylomicron enters in 
to the circulation, apolipoprotein C and apoE are combine with it in lymph and 
plasma. The lipoprotein lipase located on the capillary walls hydrolyzes triglycerides 
to fatty acids and glycerol. Some components of chylomicrons are reattached with 
lipoproteins where as other remnants are cleared by chylomicron remnant receptors 
present in the liver.  In the liver cells the cholesterol is utilized and apolipoproteins 
are catabolized. Ultimately the exogenous pathway delivers triglycerides to adipose 
tissue and muscle while cholesterol to liver (Crook, 2012; Ducharme and 
Radhamma, 2008).  
 
2.8.2 Endogenous pathway 
Liver is the major source of endogenous lipids in the body. The endogenous 
pathway of lipid metabolism involves the synthesis of lipids in the liver and they are 
transported by lipoproteins. Triglycerides are synthesized from fatty acids, glycerol 
from glucose and cholesterol from chylomicron remnants via exogenous pathway or 
synthesized locally.  From the liver, these lipids are transported by VLDL.  
VLDL is a large triglyceride with apoproteins. During circulation it adds 
apoC from HDL. Lipoprotein lipase hydrolyzes VLDL in the peripheral tissues. This 
leads to the formation of IDL or hepatic uptake, later converted to LDL by the action 
of hepatic liapse. LDL is rich in cholesterol and containing only apoB. 70% of the 
total plasma concentration is represented by LDL. In the cell, LDL is broken down 
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and release cholesterol by lysosomes. This cholesterol is utilized to synthesis steroid. 
Almost all the plasma LDL is removed by LDL receptors. If the LDL concentration 
is excessive then it can infiltrate tissues and cause damage. Removal of 
reticuloendothelial system is an alternative method to remove oxidized LDL, called 
as scavenger cell pathway. Reduced synthesis of LDL receptors in the cells activates 
the enzyme acylcoenzymeA cholesterol acyltransferase (ACAT), so the free 
cholesterol is esterified into cholesterol ester, storage form of cholesterol in the cell 
(Crook, 2012; Ducharme and Radhamma, 2008; Daniels et al., 2009).  
The dietary intake of saturated fat rich food (egg yolk, red meat and dairy 
products) influences the endogenous pathway. High saturated fat can suppress the 
LDL receptors there by alter the cholesterol metabolism. Transport of exogenous 
cholesterol and endogenous pathway of cholesterol synthesis is illustrated in Figure 
2.6.   
 
2.8.3 Reverse cholesterol transport 
Reverse cholesterol transport is the process of transport of non-hepatic cell 
cholesterol to liver involving HDL. HDL has an important role in the reverse 
transport of cholesterol. The HDL is synthesized from liver as well as intestine. They 
secrete HDL, which is rich in free cholesterol, phospholipids, apoA and apoE. HDL 
also carries apoC when the VLDL or chylomicron levels are low. 
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Figure 2.6: Transport of exogenous cholesterol and endogenous pathway of 
cholesterol synthesis- adapted from Daniels et al., (2009).  
 
HDL also can be formed from the surface caot of VLDL and chylomicrons. 
The esterification of free cholesterol is catalyzed by an enzyme lecithin-cholesterol 
acyltransferase (LCAT) present on HDL. LCAT is activated by apoA1. Most of these 
esterified cholesterol is transferred to LDL, VLDL and chylomicron remnants there 
by reaches the liver. Some cholesterol may be stored in core HDL particle and take 
directly to the liver. Apart from the removal cholesterol from cells, HDL also has 
other functions. HDL contains enzymes such as paroxanase, which may possess 
antioxidant capacity. Increased atherosclerotic plaque stability, protection of LDL 
from oxidation and maintaining the vascular integrity properties are exhibited by 
HDL (Crook, 2012; Ducharme and Radhamma, 2008; Groen et al., 2014). The 
reverse cholesterol pathway is depicted in Figure 2.7.  
